Checkpoint Inhibitor denied as not FDA-approved for this use by UnitedHealthcare?

UnitedHealthcare's specific coverage criteria for checkpoint inhibitor are defined in its own published medical/coverage policy and the FDA-approved prescribing label. A successful appeal documents that your medical records satisfy each criterion those sources list — confirmed diagnosis, any required prior treatments (with dates and outcomes), and clinical severity. If the exact criteria weren't included with your denial, request them in writing; your appeal then maps each requirement to the matching fact in your chart.

## Why UnitedHealthcare Denied Your Checkpoint Inhibitor — "Not FDA-Approved"

A "not FDA-approved" denial from UHC for a checkpoint inhibitor almost always signals one of three situations: the drug is being used off-label for a tumor type or treatment line not listed in its FDA-approved indications; the FDA approval exists but UHC's coverage policy has not yet been updated to reflect a recent label expansion; or there was a coding error — the ICD-10 diagnosis submitted does not match an approved indication in UHC's system.

This denial is frequently wrong as a factual matter — many checkpoint inhibitor uses that UHC labels "not FDA-approved" are in fact FDA-approved or compendia-supported, and federal law requires coverage of compendia-listed oncology uses regardless of whether the insurer considers them "approved."

## Federal Appeal Framework

• Internal appeal: File within 180 days. Expedited review (72-hour decision) is available when delay poses a serious health risk.
• ACA §2719 external review: This is often the strongest path for not-FDA-approved denials because the external reviewer applies objective standards — FDA approval status and compendia listings — rather than UHC's internal coverage policy.
• ERISA §503 (employer plans): You are entitled to the specific coverage criteria and clinical evidence UHC used to make the determination.
• State law protections: Many states explicitly require coverage of compendia-supported off-label oncology drugs; confirm whether your plan is state-regulated or ERISA-governed.

## Documentation to Gather

1. FDA approval confirmation: Print or screenshot the current FDA-approved prescribing label for the specific checkpoint inhibitor from FDA.gov or the manufacturer. If the use is within an approved indication, this alone can overturn the denial. 2. Compendia listing (for off-label use): Ask the oncologist to identify the NCCN, Micromedex, or DrugDex entry for the specific off-label use — this is the statutory basis for mandatory coverage in most states and under many employer plans. 3. Diagnosis coding review: Verify that the ICD-10 codes submitted on the claim and PA request match the FDA-approved indication as precisely as possible; a coding correction sometimes resolves this denial without a full appeal. 4. Prescriber letter: Should confirm the approved or compendia-supported indication, explain the patient's diagnosis in relation to that indication, and address any UHC policy objection directly. 5. UHC's coverage policy: Obtain the specific policy document UHC applied and identify whether it has been updated to reflect current FDA approvals.

## Criteria-Mapping Structure

Address the FDA-approval question directly and first: confirm approval status, cite the label indication, and map the patient's diagnosis and biomarker profile to it. If off-label, pivot to the compendia argument and cite the applicable guideline. Then address each of UHC's specific coverage criteria with patient-specific evidence. The external review track is particularly effective here because IROs are required to apply objective FDA and compendia standards, not insurer-internal definitions.